marketshareAI
Theme

HUTCHMED (China) Limited

HCMHealthcare
196.50GBX
1.81%
Market Cap
1.69B
Volume
1.03k
4% of avg
P/E Ratio
3906.93
EPS (TTM)
0.05
Beta
0.51
Day Range
192.38p - 201.00p
52 Week Range
185.50p196.50p292.00p
196.50p

Upcoming Events

Q4 2025
Completion of enrollment for the SAFFRON global Phase III study for second-line EGFR-mutated NSCLC patients with MET amplification or overexpression
High Impact Event
January 1, 2026
Updated NRDL effective date
High Impact Event
Q1 2026
Topline results from the ESLIM-02 study in second-line warm autoimmune hemolytic anemia (wAIHA)
High Impact Event
Late 2026
Topline results from the SANOVO study expected
High Impact Event
Q2 2026
Resubmission of the new drug application for second-line immune thrombocytopenia (ITP)
High Impact Event
H1 2026
Topline results from the SAFFRON study expected
High Impact Event
HCM
NEUTRAL

HUTCHMED Initiates Development of ATTC Candidate

The biopharmaceutical company has initiated global clinical development of a new ATTC candidate for treating solid tumors.

HCM
GOOD

HUTCHMED Announces Expanded NRDL and Commercial Insurance Drug List Coverage in China

The healthcare company has secured expanded coverage for its key products in China's drug reimbursement and insurance schemes, boosting patient access.

HCM
NEUTRAL

HUTCHMED Highlights Data at ESMO and ASH

The biopharmaceutical company is presenting data on several of its drug candidates at upcoming medical conferences.

HCM
NEUTRAL

HUTCHMED Completes Enrollment for SAFFRON Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Lung Cancer

The biopharmaceutical company has completed enrollment for a global Phase III trial studying a combination therapy for certain lung cancer patients.

HCM
NEUTRAL

HUTCHMED Unveils Innovative ATTC Platform and Highlights Pipeline Progress

The biopharmaceutical company unveils its new ATTC platform for precision oncology and provides updates on the advancement of its late-stage drug pipeline.

HCM
NEUTRAL

HUTCHMED Presents Data at AACR NCI EORTC

The biopharmaceutical company presents preclinical data for its HMPL-A251 drug candidate at a cancer therapeutics conference.

HCM
NEUTRAL

HUTCHMED Announces Vesting of LTIP Awards for Non-Executive Directors

The biopharmaceutical company has announced the vesting of long-term incentive plan awards for its non-executive directors.

HCM
NEUTRAL

HUTCHMED Appoints Independent Non-executive Director

The healthcare company has appointed a new Independent Non-executive Director with extensive experience in oncology research and clinical trials.

HCM
NEUTRAL

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

The biopharmaceutical company provides an update on the FRUSICA-2 registration trial evaluating the fruquintinib and sintilimab combination for the treatment of advanced renal cell carcinoma.

HCM
NEUTRAL

HUTCHMED Highlights Data to be Presented at ESMO

The biopharmaceutical company is presenting new data from several studies of its compounds at the upcoming ESMO Congress.